Fed. Circ. Affirms Bristol-Myers, Pfizer Win In Eliquis IP Row
The Federal Circuit on Friday affirmed that two patents on Bristol-Myers Squibb and Pfizer's blockbuster blood clot treatment Eliquis are valid and infringed by generic manufacturers, with the pharmaceutical companies saying...To view the full article, register now.
Already a subscriber? Click here to view full article